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LEARNING OBJECTIVES:
After completing this course, the reader will be able to:
1. Compare outcomes in patients treated with capecitabine plus CPA with those of capecitabine monotherapy and
combination therapy with bevacizumab, sorafenib, or ixabepilone.
2. Identify patients for whom single-agent capecitabine is recommended.
This article is available for continuing medical education credit at CME.TheOncologist.com.CME
ABSTRACT
Background. Interest in oral agents for the treatment of met-
astatic breast cancer (MBC) has increased because many pa-
tients prefer oral to i.v. regimens. We evaluated a simple oral
combination of capecitabine with cyclophosphamide (CPA)
for MBC.
Methods. The trial was designed to determine whether or
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not combination therapy would achieve a 42% response rate
(RR) using the Response Evaluation Criteria in Solid Tumors
(RECIST) in MBC. Patients with two or fewer prior chemo-
therapy regimens for MBC were eligible. Those with estrogen
receptor–positive MBC had to have progressed on endocrine
therapy. Patients had measurable disease or elevated mucin
(MUC)-1 antigen and received CPA, 100 mg daily on days
1–14, and capecitabine, 1,500 mg twice daily on days 8–21, in
21-day cycles.
Results. In 96 eligible patients, the median progression-
free survival (PFS) interval was 5.9 months (95% confi-
dence interval [CI], 3.7–8.0 months) and median overall
survival (OS) time was 18.8 months (95% CI, 13.1–22.0
months). The RR was 36% (95% CI, 26%–48%) in 80 pa-
tients with measurable disease. The MUC-1 antigen RR
was 33% (95% CI, 20%–48%), occurring in 15 of 46 pa-
tients with elevated MUC-1 antigen. Toxicity was mild,
with no treatment-related deaths.
Conclusions. PFS, OS, and RR outcomes with capecit-
abine plus CPA compare favorably with those of capecit-
abine monotherapy and combination therapy with
bevacizumab, sorafenib, or ixabepilone. The addition of
these other agents to capecitabine does not improve OS
time in MBC patients, and this single-arm study does not
suggest that the addition of CPA to capecitabine has this
potential in an unselected MBC population. When OS pro-
longation is the goal, clinicians should choose single-agent
capecitabine. The Oncologist 2012;17:179–187
INTRODUCTION
There is continued interest in oral agents for the treatment of
metastatic breast cancer (MBC) patients, particularly because
these patients report a preference for oral, home-based therapy
over i.v., office- or clinic-based regimens [1]. However, pa-
tients are generally not willing to sacrifice efficacy for an oral
therapy over an i.v. therapy [2], nor are they likely to prefer an
oral regimen if the toxicity is higher [3]. With these parameters
in mind, we endeavored to develop a well-tolerated, effica-
cious, all-oral combination chemotherapy regimen for the
treatment of MBC patients.
There are two independent scientific justifications for com-
bination therapy with capecitabine, an approved oral agent in
breast cancer, with cyclophosphamide (CPA). First, there is
hypothesized synergy between capecitabine and CPA. Cape-
citabine is an oral prodrug of 5-fluorouracil (5-FU). Capecit-
abine is converted to 5-FU preferentially in tumors, by a three-
step process ending with the enzyme thymidine phosphorylase
(TP) [4]. Both preclinical and clinical studies have shown that
TP expression in cancers is increased by administration of a
number of chemotherapy agents, including CPA [5, 6]. Pre-
clinical xenograft breast tumor models have demonstrated syn-
ergistic inhibition of tumor growth with capecitabine in
combination with CPA [7].
The second scientific rationale is based on the continuous
scheduling of capecitabine and CPA used in this trial. Metro-
nomic chemotherapy is the frequent administration of cyto-
toxic drugs at doses that are low enough to avoid dose-limiting
adverse effects, which would otherwise require rest periods
[8]. Metronomic therapy may target tumor cells indirectly by
inhibiting angiogenesis and vasculogenesis through continu-
ous exposure of the more slowly proliferating tumor endothe-
lial cells to cytotoxic therapy [9]. Metronomic scheduling of
well-tolerated doses of CPA and capecitabine may take advan-
tage of a synergistic cytotoxic interaction between the drugs, as
well as provide a potential antiangiogenic effect, with less tox-
icity than with alternative regimens.
We hypothesized that elderly patients may particularly bene-
fit from an all-oral, metronomic approach to treatment. Weekly
i.v. taxane therapy has been evaluated as a gentler and better tol-
erated therapy in this population [10, 11]. Barriers to this treat-
ment could include problems with i.v. access in elderly
individuals and transportation issues for weekly administration.
An all-oral combination therapy that provides greater patient ben-
efit than existing single-agent oral or i.v. therapies would repre-
sent a significant clinical advance and potentially a cost savings
[12].
This study piloted the use of the serum mucin (MUC)-1 anti-
gens CA 27–29 and CA 15–3 as surrogate markers of response in
a SWOG clinical trial. It has been shown that a 50% decline in
serum prostate-specific antigen (PSA) in prostate cancer patients
is a statistically significant factor associated with survival, and
thus PSA has been proposed as a useful surrogate endpoint to be
used in phase II chemotherapy trials in prostate cancer patients,
whose disease is often bone predominant and poorly measurable
[13, 14]. Likewise, a 50% decline in CA-125 in ovarian cancer
patients was strongly correlated with response rates (RRs) using
standard criteria, and response definitions based on a 50% or 75%
decrease in CA-125 level accurately predicted which drugs in
phase II trials for relapsed ovarian cancer were active and justified
further investigation [15]. In breast cancer, the MUC-1–associ-
ated antigens CA 27–29 and CA 15–3 may represent a similar sit-
uation [16–18]. These antigens are closely related and give
comparable assay results [19]. Moreover, a 20% reduction in
MUC-1 antigen levels suggested a longer time to progression in
pretreatment marker-positive patients [19].
Despite numerous studies documenting the utility of
MUC-1 antigens in monitoring response in clinical practice,
the use of change in MUC-1 antigen levels as a surrogate end-
point in the design of phase II trials has been limited, perhaps
because of some inherent limitations. First, MUC-1 antigens
are elevated in only 70% of patients with documented met-
astatic disease, and more often in bone- and visceral-predom-
inant disease than in soft tissue disease. The kinetics of MUC-1
antigens are such that early measurement may be misleading,
because up to one third of responding patients may have an ini-
tial increase in levels at 15 days and 30 days, followed by a
return to baseline levels at 60 days [20 –22]. Additionally,
hand–foot syndrome, pulmonary fibrosis, hepatic toxicity, and
gastrointestinal inflammation may be associated with false el-
evations in MUC-1 antigens [23].
Despite these limitations, MUC-1 antigens have the poten-
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tial to serve as tools for estimating treatment response in pa-
tients with metastatic disease not measurable radiographically.
In the area of breast cancer, a significant subset of patients suf-
fers from bone-predominant disease that is nonmeasurable us-
ing the Response Evaluation Criteria in Solid Tumors
(RECIST), thus making them ineligible for many clinical tri-
als. We planned to use the experience gained in this trial to
guide future trial designs of SWOG.
MATERIALS AND METHODS
Patient Eligibility
This prospective clinical trial (ClinicalTrials.gov identifier,
NCT00107276) was conducted by SWOG, a federally funded
clinical trials cooperative group. Patients aged 18 years with
MBC and zero, one, or two prior chemotherapy regimens for
metastatic disease were eligible to participate. Patients with es-
trogen receptor (ER) MBC must have progressed on at least
one endocrine therapy in the metastatic setting. RECIST-
measurable disease was not required for all patients; however,
in the absence of measurable disease, patients were required to
have a MUC-1 antigen level (either CA 15–3 or CA 27–29)
over two times the upper limit of normal (2 ULN) and a
MUC-1 antigen level documented to have increased by 1.5
prior to registration. Patients with symptomatic brain or central
nervous system (CNS) metastases were excluded, although
treated CNS metastatic disease was allowed if radiation ther-
apy had been completed at least 8 weeks previously. Prior
capecitabine or oral CPA therapy and concurrent antineoplas-
tic therapy (radiation, chemotherapy, immunotherapy, biolog-
ical therapy, hormonal therapy) were not allowed, with the
exception of bisphosphonates. Other eligibility criteria were: a
Zubrod performance status score of 0–2, adequate renal func-
tion (creatinine clearance 40 mL/minute by the Cockcroft
and Gault formula), the ability to take oral medications, no
prior unanticipated severe reaction to fluoropyrimidine ther-
apy, no known sensitivity to 5-FU, and no known dihydropy-
rimidine dehydrogenase deficiency. Patients requiring full-
dose anticoagulation with warfarin were excluded because of
the interaction between warfarin and capecitabine. The study
protocol was approved by the institutional review boards at
participating institutions. Patients were informed of the inves-
tigational nature of the study and provided written informed
consent in accordance with institutional and federal guidelines,
including informed consent regarding the banking of whole
blood and serum specimens to explore relevant molecular pa-
rameters.
Study Treatment
CPA (100 mg) was given on days 1–14, with capecitabine
(1,500 mg twice daily) beginning on day 8 and continuing to
day 21 (total of 14 days), on a 21-day schedule. This alternat-
ing schedule was designed to exploit the hypothesized induc-
tion of TP by CPA. Flat dosing of the oral agents was used in
view of published data indicating that the clearance of both
drugs is independent of body surface area [24, 25]. Patients
with a lower creatinine clearance (40 –50 mL/minute) were
started at capecitabine dose level 1 (1,000 mg twice daily).
The CPA dose was based on a phase III clinical trial evaluating
a similar combination [26]. Chemotherapy was given for eight
cycles. Treatment beyond eight cycles was at the discretion of
the treating physician.
The continuous therapy was interrupted in cases of toxic-
ity, and treatment was resumed once the toxicity had resolved
as specified for that calendar day, with dose adjustment as re-
quired. CPA was held if the absolute neutrophil count was
1,000/mm3, if the platelet count was 75,000/L, or for any
nonhematological grade 3 or 4 toxicity attributable to the drug.
Dosing of capecitabine was interrupted for hand–foot syn-
drome, diarrhea, or mucositis grade 2 that developed at any
time while the patient was receiving the drug, and the dose was
subsequently reduced for grade 3–4 toxicity or for grade 2 tox-
icity that occurred twice. Dose levels of capecitabine were:
level 0, 1,500 mg twice daily; level 1, 1,000 mg twice daily;
level 2, 500 mg in the morning and 1,000 mg in the evening;
and level 3, 500 mg twice daily. Dose escalations were not
allowed. If a dose reduction was mandated by toxicity, dose
re-escalation was not allowed even if the toxicity resolved. Use
of filgrastim was not allowed, but erythropoietin was allowed
at the discretion of the treating physician.
Study Assessments
Baseline evaluation included a history and physical examina-
tion, weight measurement, assessment of performance status,
CBC and differential, and measurement of serum bilirubin, se-
rum glutamic oraloacetic transaminase or serum glutamic py-
ruvic transaminase, alkaline phosphatase, creatinine, calcium,
potassium, and sodium levels. For patients without measurable
disease, MUC-1 antigen elevation (CA 15–3 or CA 27–29)
was required for study eligibility. Patients were requested to
provide a baseline serum and whole blood sample for banking
for future correlative studies. Baseline imaging was performed
as required by location of metastases, including a physical ex-
amination, computed tomography scan of the chest, abdomen,
and pelvis, bone scan, and x-rays. Response to treatment was
evaluated at the beginning of odd-numbered treatment cycles
using the RECIST (version 1.0). MUC-1 antigen was mea-
sured each cycle. Toxicities were graded using the National
Cancer Institute Common Terminology Criteria for Adverse
Events (version 3.0).
Statistical Analysis
The objectives of this trial were to: (a) evaluate the RRs (com-
plete response [CR] and partial response [PR], confirmed and
unconfirmed) to combination simple oral therapy with CPA
and capecitabine in the subset of patients with measurable dis-
ease, (b) estimate progression-free survival (PFS) and overall
survival (OS) outcomes, (c) evaluate the toxicity of this drug
combination, (d) explore the use of MUC-1 antigens (CA
27–29 or CA 15–3) as surrogates for clinical benefit in patients
with nonmeasurable disease, and (e) establish a serum and
whole blood specimen bank for MBC for future correlative
studies.
We planned to enroll 96 patients in a single stage over 4
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years with 2 years of follow-up after the last enrollment. Be-
cause response in patients aged 65 years was of special in-
terest, a subset analysis was prospectively planned for this age
group.
Efficacy was evaluated using the proportion of responders
to treatment, defined as those with a CR or PR. We assumed
that 75% of the patients would have measurable disease using
the RECIST. We anticipated a 25% RR with single-agent stan-
dard treatment. The combined CPA and capecitabine therapy
would be of interest if the RR was 42%. Assuming a signifi-
cance level of   0.05 (one sided) and 72 patients with mea-
surable disease, the power to detect this difference would be
92% overall. If 47 patients aged 65 years were enrolled, then
the power would be 80% to detect an absolute 17% higher RR.
Analyses of PFS and OS outcomes were performed using
Kaplan–Meier analysis. The PFS interval was defined as the
difference between the registration date and date of progres-
sion or death resulting from any cause, or the last follow-up
date if progression or death was not observed. The OS duration
was the time from registration to death resulting from any
cause, or the last follow-up date in censored individuals. If the
median OS time was 12 months with standard treatment,
then a longer median OS time of 16 months could be detected
with 90% power and   0.05 (one sided).
The trial’s objectives included an exploration of the use of
MUC-1 antigens (CA 27–29 or CA 15–3) as surrogates for
clinical benefit in patients with nonmeasurable disease, and the
trial had prespecified definitions for MUC-1 response determi-
nation. The set of patients analyzed for overall MUC-1 antigen
response was all patients with a baseline CA 27–29 or CA 15–3
level 2 ULN. Only MUC-1 values recorded during the
treatment period were included in the assessment of MUC-1
response. An initial spike in a MUC-1 antigen level did not
change the baseline comparator, nor did MUC-1 antigen ele-
vation determine progression if the patient did not clinically
progress. A MUC-1 antigen PR (mPR) was defined as a 50%
decline in MUC-1 antigen compared with baseline that per-
sisted for 21 days. A MUC-1 antigen CR (mCR) was defined
as a decrease in a MUC-1 antigen level into the normal range
that persisted for 21 days. MUC-1 antigen progressive dis-
ease (mPD) was defined as an increase in a MUC-1 antigen
level 50% as the best response. MUC-1 antigen stable dis-
ease (mSD) was a MUC-1 antigen response that did not fit any
of the above categories. The overall MUC-1 antigen RR (mRR)
was defined as the number of patients with mCR or mPR divided
by the number of patients with an elevated baseline MUC-1 anti-
gen level. Patients without a MUC-1 antigen response assessment
were considered to have not responded when calculating the
mRR. The overall mRR (mCR or mPR) is provided with an exact
95% two-sided confidence interval (CI) using standard methods
based on the binomial distribution. As a supplemental analysis,
the rate of disease control (mCR, mPR, or mSD) was summarized
in the same way as the overall mRR.
RESULTS
Between August 15, 2005 and September 1, 2007, 112 patients
were registered from 26 institutions. Patient characteristics are
summarized in Table 1. Sixteen patients were ineligible. Rea-
sons for ineligibility included: no measurable disease and
MUC-1 antigen ineligible (10 patients), ER disease but no
prior endocrine therapy (four patients), and too many prior
chemotherapies (two patients).
Eighty eligible patients had measurable disease at baseline.
Six patients with inadequate or delinquent disease assessments
were assumed to be nonresponders for the purpose of RR esti-
mation. There were 29 responses (four CRs and 25 PRs)
among the 80 patients with measurable disease, for an RR of
36% (95% CI, 26%–48%) (Table 2). The RRs for patients with
zero, one, and two prior metastatic chemotherapy regimens
were 32%, 40%, and 45%, respectively (Table 3).
Evaluation of efficacy in the elderly population was of spe-
cific interest in this study. Twenty-five patients aged 65
years had measurable disease, and the RR in this subgroup was
significantly lower than that observed in the younger popula-
tion, estimated at 16% (95% CI, 5%–36%; p  .013) (Table 3).
When SD is included, the clinical benefit rate (CBR) was 68%
overall, with little difference between women aged 65 years
(69%) and those aged 65 years (64%) (p  .80).
Ninety-six eligible patients with follow-up data were eval-
uated for survival endpoints. Ninety-two of the 96 experienced
PD or death. Seventy-nine deaths were recorded among the 92
patients. The median PFS interval was 5.9 months (95% CI,
3.7– 8.0 months) and the median OS time was 18.8 months
(95% CI, 13.1–22.0 months) (Fig. 1). For patients with zero,
one, or two prior metastatic chemotherapy regimens, the me-
dian PFS intervals were 6.4 months, 6.3 months, and 4.1
months, respectively. The median OS times for patients with
zero, one, or two prior chemotherapy regimens were 24.1
months, 17.3 months, and 8.6 months, respectively. Tests for
trend confirmed that PFS and OS times decreased with increas-
ing number of previous regimens (p  .012 and p  .001, re-
spectively). For patients aged 65 years and 65 years, the
median PFS intervals were 2.9 months and 7.0 months (not sig-
nificant [NS]), respectively. The median OS times for patients
aged 65 years and 65 years were 17.3 months and 19.9
months (NS).
Ninety-five patients were evaluated for adverse events and,
overall, the treatment was associated with low toxicity (Table
4). One patient with no toxicity assessments done prior to pro-
gression was not evaluable for toxicity assessment. There were
no treatment-related deaths reported. Four patients experi-
enced grade 4 toxicities: lymphopenia (three cases) and throm-
bosis/embolism (one case). Thirty-three patients experienced
grade 3 toxicities as the maximum degree, including leukope-
nia (15 patients); hand–foot syndrome (seven patients); and fa-
tigue, diarrhea, and dehydration (two patients each).
Of the 96 eligible patients, two did not have MUC-1 testing
prior to treatment initiation. Of the remaining 94 patients, 46
(49%) had MUC-1 values 2 ULN at baseline. Four of the
46 (9%) had sustained subsequent normal MUC-1 values dur-
ing treatment, thus meeting the definition of mCR. An addi-
tional 11 patients (24%) had a 50% reduction in MUC-1 level
from baseline and were categorized as mPR. Eleven had an in-
crease 50% from baseline and were categorized as mPD. An
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additional four patients (9%) with initial abnormal values did
not have a follow-up MUC-1 assessment during treatment and,
thus, were categorized as nonresponders. The remaining 16 pa-
tients (35%) did not meet any of the aforementioned criteria
and were categorized as mSD. Therefore, the mRR (mCR and
mPR) among those with elevated initial MUC-1 values was
33% (15 of 46) with a 95% CI of 20%–48%. If those with mSD
are included, the MUC-1 antigen CBR is 67% (31 of 46), with
a 95% CI of 52%–80%.
Thirty patients had disease measurable by both methods.
Ten of 30 were responders as evaluated using the RECIST,
nine of 30 had a response using MUC-1 assessment, and seven
of 30 patients had a response using both methods (Fig. 2). The
Table 1. Patient characteristics at baseline
Characteristic n of patients %
n enrolled 112
n eligible 96
Age, yrs (median  59)
34–49 22 23
50–64 44 46
65–88 30 31
Menopausal status
Premenopausal 18 19
Postmenopausal 78 81
Metastatic sitea
Bone 53 55
Lung 44 46
Liver 38 40
Lymph nodes 26 27
Pleura 11 11
Other 48 50
n of metastatic sites
1 25 26
2 30 31
3 41 43
Tumor hormone receptor status
ERPgR 45 48
ERPgR 11 12
ERPgR 2 2
ERPgR 36 38
Missing 2
HER-2/neu status
Absent 7 7
Negative 78 82
Positive 6 6
Equivocal 4 4
Prior adjuvant therapy
None 26 27
CT 30 31
HT 9 9
CT  HT 31 32
Prior therapy for metastatic disease
None 17 18
CT 21 22
HT 36 37
CT  HT 22 23
n of prior metastatic CT regimens
0 53 55
1 30 31
2 13 14
aMultiple sites possible.
Abbreviations: CT, chemotherapy; ER, estrogen receptor;
HER-2, human epidermal growth factor receptor 2; HT,
hormone therapy; PgR, progesterone receptor.
Table 2. Response for measurable patients
Response Evaluation Criteria in
Solid Tumors n %
Complete response 4 5%
Partial response 25 31%
Stable disease/no response 25 31%
Progressive disease 18 23%
Symptomatic deterioration 2 3%
Assessment inadequate 6 8%
Total 80 100%
Table 3. Response rates for measurable patients by prior
therapy, ER status, and age subgroup
n Responses
Response
rate 95% CI
All patients 80 29 36% 26%–48%
n of prior
chemotherapy
regimens for
metastatic
disease
0 44 14 32% 19%–48%
1 25 10 40% 21%–61%
2 11 5 45% 17%–77%
ER status
Positive 41 17 41% 26%–58%
Negative 38 12 32% 17%–49%
Missing 1
Age subgroup
65 yrs 25 4 16%a 5%–36%
65 yrs 55 25 45%a 32%–59%
aSignificant difference, p  .013.
Abbreviations: CI, confidence interval; ER, estrogen
receptor.
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two patients who had a response using MUC-1 assessment but
not using the RECIST had SD per the RECIST.
The MUC-1 values of all 16 patients with nonmeasurable
disease were elevated at baseline as part of the requirement for
eligibility. Six of these 16 patients had bone as the only site of
disease, and 13 of these 16 patients had at least one bone me-
tastasis. Six of these 16 were responders (two with mCR and
four with mPR) using the MUC-1 criteria, giving an mRR of
38% (95% CI, 15%– 65%). Six more had mSD, and the re-
maining four patients had mPD using the MUC-1 criteria. The
mRR in RECIST-measurable patients was 30% (nine of 30)
with a 95% CI of 15%–49%. Overall, the RRs in the MUC-1
subsets were similar to the RECIST RRs (Fig. 2).
DISCUSSION
In this trial of combination capecitabine and CPA in MBC pa-
tients treated with two or fewer prior chemotherapy regimens,
the primary RR, PFS, and OS outcomes compare favorably
with those from historical reports of single-agent capecitabine.
Toxicity was mild, with few serious adverse events reported in
a multicenter setting that included both academic and commu-
nity-based practices.
The protocol-defined historical comparator was a 25% RR.
Published single-agent capecitabine phase II studies have doc-
umented RRs of 15%–28% [27–30], and recent randomized
studies using capecitabine as the control arm have similarly
shown RRs with single-agent capecitabine of 14%–31% [16,
18, 19]. In combination with oral CPA, we observed a 36% RR
overall, but note that this did not reach our goal of a 42% RR.
It is, however, consistent with the 36% RR observed with con-
current capecitabine–CPA therapy recently published by
Tanaka et al. [31].
The regimen had a disappointing RR in the elderly. How-
ever, CBRs were comparable between age groups because SD
was more often recorded in the elderly. The PFS interval was
shorter in older women, but the difference was not statistically
significant.
Closer review of the data does not provide further expla-
nation of the low RR in the elderly. The older women tended to
have more ER and progesterone receptor–positive disease
and were treated with fewer previous regimens for metastatic
disease. Dose delays and modifications were not obviously
more common in elderly patients, but it should be noted that
the study was not designed to look for a difference in these fac-
tors. Overall, these results suggest a somewhat lesser activity
of this chemotherapy in elderly patients, but advocate that el-
derly patients may still receive clinical benefit.
The patient population in this study included both pre-
treated and chemotherapy-naïve patients, and reflects a typical
MBC population. Our results have implications for clinical
trial design for MBC. First, these data do not support the rou-
tine exclusion of MBC patients who have had prior chemother-
apy regimens from phase II clinical trials in which the RECIST
RR is the primary endpoint, because there was little difference
in the RR between the subsets of pretreated and chemotherapy-
naïve patients. Furthermore, these data emphasize the sensitiv-
ity of survival outcomes to the number of prior chemotherapy
regimens and highlight the importance of stratifying or con-
trolling for these factors when survival outcomes are primary.
The 16 patients enrolled with nonmeasurable disease are of
specific interest to determine whether MUC-1 antigen positivity
should satisfy an eligibility criterion in future SWOG studies. In
this trial, 13 of 16 patients had bony disease, and in six of 16, bone
was the only site of disease. The mRR in those 16 patients was
comparable with the RECIST RR in the measurable population of
patients. Furthermore, there was good concordance between
RECIST response and MUC-1 response in patients measurable
by both methods. Overall, these data encourage further investiga-
tion of mRR as a surrogate marker of efficacy in patients with
bone-predominant breast cancer, in whom the disease is poorly
measurable radiographically. Continuing use of MUC-1 antigen
positivity as an eligibility criterion in SWOG studies will provide
an opportunity for this clinically relevant patient population to be
included in early-phase clinical trials designed to look for signals
of treatment efficacy.
It is interesting to consider this regimen in the context of
other possible capecitabine combinations. Several recently re-
ported randomized trials have examined capecitabine alone
versus in combination with other therapies: with bevacizumab,
an i.v. monoclonal antibody directed against vascular endothe-
lial growth factor (VEGF) in first-line and second-line treat-
ment for advanced breast cancer [32, 33]; with sorafenib, an
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Figure 1. Overall survival (A) and progression-free survival (B)
outcomes in the Southwest Oncology Group S0430 trial.
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oral tyrosine kinase inhibitor with many targets, including
VEGF, in first-, second-, and third-line therapy of advanced
breast cancer [34]; and with ixabepilone, a newly approved
epothilone cytotoxic in the setting of prior anthracycline and
taxane therapy [35]. The clinical data from these studies, as
published or presented recently at major oncology meetings,
are summarized Table 5. The RR, PFS, and OS results with
CPA and capecitabine appear to be similar to those with com-
binations of capecitabine with bevacizumab, sorafenib, and
ixabepilone, taking into consideration the prior number of ther-
apies and proportion of ER versus ER patients. However,
intertrial comparisons must be interpreted with caution be-
Table 4. Number of patients with a given type and grade of adverse event
Adverse event
Grade
Unknown 0 1 2 3 4 5
Antidiuretic hormone 0 94 0 0 1 0 0
Alanine aminotransferase 0 89 4 1 1 0 0
Alkaline phosphatase 0 85 8 1 1 0 0
Dehydration 0 92 0 1 2 0 0
Diarrhea 0 66 25 2 2 0 0
Dyspnea 0 87 7 0 1 0 0
Fatigue 0 38 35 20 2 0 0
Febrile neutropenia 0 94 0 0 1 0 0
Hand–foot syndrome 0 58 14 16 7 0 0
Hemoglobin 0 57 24 13 1 0 0
Hypokalemia 0 89 5 0 1 0 0
Hyponatremia 0 89 5 0 1 0 0
Leukocytopenia 0 52 17 11 15 0 0
Lymphopenia 0 74 2 6 10 3 0
Mood alteration: depression 0 90 2 2 1 0 0
Nausea 1 43 42 8 1 0 0
Neutropenia 0 66 8 14 7 0 0
Thrombocytopenia 0 82 11 1 1 0 0
Pruritus 0 94 0 0 1 0 0
Rash 0 91 3 0 1 0 0
Thrombosis/embolism 0 93 0 0 1 1 0
Weight loss 0 88 6 0 1 0 0
Maximum grade any adverse event 1 6 17 34 33 4 0
Adverse events unlikely or not related to treatment and those with maximal grade 2 were excluded.
Figure 2. Response rate (RR) by the Response Evaluation Criteria in Solid Tumors (RECIST) and mucin (MUC)-1 criteria.
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cause there are often significant differences in the clinical trial
populations.
CONCLUSION
Randomized trials have failed to show that the addition of be-
vacizumab, sorafenib, or ixabepilone to capecitabine as a sin-
gle agent leads to longer OS times in MBC patients. Nor do our
results suggest that the addition of CPA to capecitabine has this
potential in an unselected MBC population. Therefore, we
conclude that single-agent capecitabine should continue to be
used in patients without immediately life-threatening or highly
symptomatic disease.
Combination chemotherapy regimens in breast cancer typ-
ically are associated with higher RRs and longer PFS times
than with single-agent regimens, but they have failed to pro-
duce an OS benefit compared with single-agent sequential
therapy. Despite this fact, we continue to be informed of trial
results that pit combination capecitabine therapies against sin-
gle-agent capecitabine therapy. We propose that any expensive
or less convenient capecitabine combination regimen in rou-
tine use based on such trial results should be tested against an-
other combination regimen. The SWOG all-oral regimen
would be of interest in randomized comparative effectiveness
studies to better evaluate costs, quality of life, and the prefer-
ences of MBC patients and their caregivers.
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